License Agreement Milestone Development Total Payments

No definition available.

Name:	immu_LicenseAgreementMilestoneDevelopmentTotalPayments
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement Milestone Payment Upon Achievement of FDA Approval

+ References

No definition available.

+ Details

Name:	immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement Milestone Sales Total Payments

+ References

No definition available.

+ Details

Name:	immu_LicenseAgreementMilestoneSalesTotalPayments
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement Upfront Fees Paid

+ References

No definition available.

+ Details

Name:	immu_LicenseAgreementUpfrontFeesPaid
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty Payments Percentage

+ References

No definition available.

+ Details

Name:	immu_RoyaltyPaymentsPercentage
Namespace Prefix:	immu_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_MajorCustomersAxis=immu_EverestMedicinesIILimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=immu_JanssenBiotechInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue Recognition - Additional Information (Details) - USD ($)			3 Months Ended
	Apr. 29, 2019	Apr. 05, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred revenues			$ 65,000,000		$ 65,000,000
Total revenues			0	$ 0
Everest Medicines II Limited
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront fees paid	$ 65,000,000.0
Milestone payment, achievement of FDA approval for sacituzumab govitecan	60,000,000.0
Milestone payment, development	180,000,000.0
Milestone payment, sales	530,000,000.0
Deferred revenues	$ 65,000,000.0
Total revenues			$ 0	0
Everest Medicines II Limited \| Minimum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Royalty payments percentage	14.00%
Everest Medicines II Limited \| Maximum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Royalty payments percentage	20.00%
Janssen Biotech Inc.
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone payment, sales		$ 15,000,000.0
Total revenues				$ 0